Repligen Corporation (RGEN) EV/EBITDA Multiple
Will robotic bioprocessing systems fuel growth for Repligen Corporation (RGEN)? Analyzing the EV/EBITDA multiple for this capital-intensive enterprise on GURU.Markets, we note that the 67.85 metric determines this level, which is supported by the development of gene therapy and R&D. The asset's stability is based on the deep integration of filters into the production lines of pharma behemoths, making a change of supplier extremely difficult.
Comprehensive metric breakdowns and analytics for repligen.com (RGEN)
- current price and projected stock value:
- market capitalization details:
- issuer book value statistics:
- debt and liquidity details:
- financial results and valuation multiples details:
RGEN - Profit After Tax|Expected Profit Repligen Corporation|RGEN - Market Cap to Earnings|Future Price to Earnings Repligen Corporation|RGEN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Repligen Inc.|RGEN - Operating profit EBITDA|Net earnings per share for the last 12 months Repligen|RGEN - Earnings per share for the last four quarters|Quarterly EPS earnings growth repligen.com|RGEN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Repligen Corporation
Analysis of all company metrics:RGEN (Repligen Corp.)
For Repligen Corporation (RGEN), whose supply chains are sensitive to geopolitical risks, the current EV/EBITDA valuation level on the GURU.Markets platform serves as an indicator of business resilience. This metric compares the company's total enterprise value, including net debt, against its operating profit, allowing investors to assess the real value of assets relative to the ability to generate cash flow regardless of the tax burden.
Competitor analysis
EV/EBITDA Multiple TEM (tempus.com)|Total Company Value to Operating Income Before Depreciation Ratio Qiagen Corp (QGEN)|Ionis Pharmaceuticals - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple aviditybiosciences.com (RNA)|CRSP: EV/EBITDA Multiple|Company Value to EBITDA GeneDx Holdings (WGS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ultragenyx Pharma|Enterprise Value to Operating Income Before Depreciation BEAM (Beam Tx)|Enterprise Value to EBITDA Ratio SRPT (Sarepta Therapeutics, Inc.)|TWST (twistbioscience.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TXG (10x Genomics)|NTLA - Enterprise Value to EBITDA Ratio|STOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BioLife|Wave Life Sciences (WVE) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|mazetx.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sionna Therapeutics|Prime Medicine Inc - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Taysha (TSHA)|QURE - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx Holdings plc MGTX|Business Value to Operating Income Before Depreciation RGNX|Solid Biosciences - EV/EBITDA Multiple|OCGN - EV/EBITDA Multiple|PACB (Pacific Biosciences of California) - Enterprise Value to EBITDA Ratio|BNTC: Enterprise Value to Operating Income Before Depreciation Ratio|DSGN (Design Therapeutics) - EV/EBITDA Multiple|rocketpharma.com (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics, Inc. (FDMT)|LXEO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT: Enterprise Value to Operating Income Before Depreciation|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation PRQR (ProQR Therapeutics N.V.)|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo Therapeutics Inc. SGMO|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Metagenomi Therapeutics MGX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|generationbio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio)|XCUR: Enterprise Value to Operating Income Before Depreciation|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PHIO (Phio Pharmaceuticals) - Enterprise Value to Operating Income Before Depreciation|MBIO: EV/EBITDA Multiple|TransCode Therapeutics, Inc. (RNAZ) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|APDN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BLUE|IPA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|OMIC (singulargenomics.com) - Company Value to Operating Income Before Depreciation Ratio|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SYRS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TBIO: EV/EBITDA Multiple|TCON - Total Company Value to Operating Income Before Depreciation Ratio|UBX (Unity Biotechnology) - EV/EBITDA Multiple
